August 15, 2024 - 🧬 [nGram] Today’s Neurology Scoop: Vaccinex SIGNAL-AD Trial Update & Quince Therapeutics' Lancet Publication

1. Vaccinex provides update on new findings for SIGNAL-AD phase 1b/2 trial of pepinemab in Alzheimer’s disease

   • Vaccinex announced new findings from the SIGNAL-AD Phase 1b/2 trial of pepinemab in Alzheimer's disease.
   • The trial is designed to evaluate the safety and efficacy of pepinemab in patients with early Alzheimer's disease.
   • Preliminary results indicate potential benefits in cognitive function and brain metabolism.
   • Vaccinex plans to pursue a development partnership to advance the clinical development of pepinemab.
   Read more
   
   

2. Quince Therapeutics announces The Lancet Neurology publication of phase 3 ATTeST clinical trial data evaluating EryDex for the treatment of ataxia-telangiectasia

   • Quince Therapeutics has published phase 3 ATTeST clinical trial data in The Lancet Neurology.
   • The trial evaluated EryDex for the treatment of ataxia-telangiectasia (A-T).
   • EryDex utilizes Quince's proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology.
   • The company plans further regulatory submissions and additional clinical trials.
   Read more